Jade Biosciences, Inc.
JBIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.3B
$21.29
▼ -0.19%
P/E
-7.74
Mkt Cap
$1.3B
52-Wk Range
$6.91–$28.00
52-Week Range
$6.91 - $28.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 167.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Validated APRIL pathway target with established biology in autoimmune disease
- First-mover advantage in APRIL-targeting therapies for IgA nephropathy
- Focused pipeline strategy reducing development complexity and capital requirements
- Addressing large unmet medical need with limited current treatment options
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
JADE-001 clinical trial initiation (H2 2025) and initial efficacy data (H1 2026)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-1.0% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying JBIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 10, 2026
Reported EPS of -$0.76 vs -$0.64 consensus (-19.4% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-19.4%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$51.00
▲ +139.5% vs $21.29
Latest: Jefferies · Aug 11, 2026
2 analysts covering
vs Industry
How JBIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related